N-[2-(4-chlorophenyl)ethyl]-4-hydroxy-1,3-dihydroisoindole-2-carbothioamide | 876066-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-[2-(4-chlorophenyl)ethyl]-4-hydroxy-1,3-dihydroisoindole-2-carbothioamide
• CAS: 876066-38-5
• 化学式: C₁₇H₁₇ClN₂OS
• 分子量: 332.854
• InChiKey: RHZNSWYMJOWUEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  isoindolin-4-ol hydrobromide 、 2-(4-氯苯基)乙基 异硫代氰酸酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以35%的产率得到N-[2-(4-chlorophenyl)ethyl]-4-hydroxy-1,3-dihydroisoindole-2-carbothioamide
  参考文献：
  名称：

  SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

  摘要：

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.055

文献信息

• [EN] BRONCHORELAXING COMPOUNDS<br/>[FR] COMPOSES BRONCHO-RELACHANTS
  申请人：RESPIRATORIUS AB

  公开号：WO2005070887A1

  公开（公告）日：2005-08-04

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts formula (I) wherein A is CHR9, wherein R9 is H, C1-C6 alkyl;n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl or R4-R7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.

  通式（I）的化合物及其药学上可接受的酸加合盐，其中A为CHR9，其中R9为H，C1-C6烷基；n为1-3；B为CHR10，其中R10为H，C1-C6烷基；m为1或2；D为O或S；E为CR11R12或NR13，其中R11和R12独立地为H或C1-C6烷基，R13为H或C1-C6烷基；F为C1-C18烷基或R4-R7环烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管收缩为特征的肺部疾病；还公开了包含通式（I）的药物组合物、药物载体和可选的抗哮喘药、其制造方法以及治疗或预防该疾病的方法。
• BRONCHORELAXING COMPOUNDS
  申请人：RESPIRATORIUS AB

  公开号：EP1708999A1

  公开（公告）日：2006-10-11
• [EN] Bronchorelaxing agents based on indol- and isoquinoline derivatives<br/>[FR] AGENTS BROCHORELAXANTS BASÉS SUR DES DÉRIVÉS ET D'ISOQUINOLÉINE
  申请人：RESPIRATORIUS AB

  公开号：WO2007011290A1

  公开（公告）日：2007-01-25

  [EN] A compound of formula (I) and its acid addition salts, wherein R1-FIj are H, lower (CrC6) alkyl; halogen; NR5R6, wherein R5, R6 are H, lower alkyl, C2-C6 acyl, SO2R7, wherein R7 is lower alkyl, CF3, aryl, substituted aryl; CN; COR8, wherein R8 is H, OH, lower alkyl, lower alkoxy; SO2R9, wherein R9 is OR10, wherein R10 is H, lower alkyl or NRnR12, wherein R11 and R12 is H or lower alkyl; ORi3, wherein R13 is H, lower alkyl, C2-C6 acyl, C1-C8 carboxy, C1-C8 carbamoyl; X is O or S; A is H, lower alkyl; B is C1-C18 alkyl optionally substituted; M is zero or 1; with the proviso that no more than three of R1-R4 are H, for treating and preventing bronchoconstructive pulmonary disease.
  [FR] Cette invention concerne un composé de formule (I) et ses sels additifs acides, formule selon laquelle R₁-R₄ sont H, alkyle inférieur (C₁-C₆) ; halogène ; NR₅R₆, lesquels R₅, R₆ sont H, alkyle inférieur, C₂-C₆ acyle, SO₂R₇, lequel R₇ est alkyle inférieur, CF₃, aryle, aryle substitué ; CN; COR₈, lequel R₈ est H, OH, alkyle inférieur, alkoxy inférieur ; SO₂R9, lequel R₉ est OR₁₀, lequel R₁₀ est H, alkyle inférieur ou NR_nR₁₂, lequel R₁₁ et R₁₂ est H ou alkyle inférieur ; ORi₃, lequel R₁₃ est H, alkyle inférieur, C₂-C₆ acyle, C₁-C₈ carboxy, C₁-C₈ carbamoyl ; X est O ou S ; A est H, alkyle inférieur ; B est C₁-C₁₈ alkyle substitué par option ; M est zéro ou ₁ ; à condition que trois R₁-R₄ au maximum soient H, pour le traitement et la prévention de la maladie pulmonaire bronchoconstructive.